SmarTrend Watching for Potential Pullback in Shares of MannKind After 3.18% Gain
Comtex SmarTrend(R) - Wed Dec 24, 5:08PM CST
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $5.50 to a high of $5.71. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high of $5.61 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MNKD: 5.68 (+0.18)
MannKind Corporation: An Analysis
Ryan Spellman - Seeking Alpha - Wed Dec 24, 8:34AM CST
Company Overview MannKind Corporation (NASDAQ: MNKD ) is a developmental biotechnology company focused on the treatment of Type 1 and Type 2 diabetes mellitus. The company's only FDA-approved product, Afrezza, is an inhalable insulin therapy for...
MNKD: 5.68 (+0.18)
Eli Lilly-Adocia Strike Deal to Develop Ultra-Rapid Insulin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 1:50PM CST
Eli Lilly and Company (LLY) and Adocia entered into a licensing agreement to develop an ultra-rapid insulin, BioChaperone Lispro, for type I and type II diabetes.
BIIB: 340.89 (+5.13), NVO: 43.80 (+1.08), LLY: 70.16 (+0.42), MNKD: 5.68 (+0.18)
Buying These 3 Stocks Is Like Making a Bet in a Burning House
George Budwell, The Motley Fool - Motley Fool - Mon Dec 22, 7:54AM CST
Source: Flickr user Mark Esau Bargain hunters are often attracted to beaten-down biotech stocks because they sometimes rebound in astonishing fashion. That said, it can be extremely difficult to separate the wheat from the chaff when mulling over...
OREX: 5.98 (+0.01), AZN: 70.44 (+0.26), VVUS: 2.99 (-0.02), AMGN: 160.67 (+3.15), AEGR: 21.59 (-0.27), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)
Could the Next Generation of Diabetes Treatments Be Found in This Illegal Drug?
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 21, 10:41AM CST
Heart disease and cancer may be the two most common direct causes of death in the United States, but a chronic disease that now affects 29.1 million people in this country and is a prime risk factor for heart disease, cancer, and...
JNJ: 104.59 (+0.31), GWPH: 68.08 (+1.82), MRK: 57.46 (+0.25), MNKD: 5.68 (+0.18)
A New Study on Diabetes Reveals Potentially Frightening News
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 20, 10:41AM CST
Based on the latest statistics from the CDC, 29.1 million people in the U.S. now have diabetes, of which more than one in four is unaware they have the chronic disease. This is up from 26 million in the CDC's last update. Further, the number of...
JNJ: 104.59 (+0.31), GWPH: 68.08 (+1.82), AZN: 70.44 (+0.26), MNKD: 5.68 (+0.18)
Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)
at The Street - Fri Dec 19, 8:02AM CST
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
VRTX: 115.15 (+1.40), GALE: 1.49 (-0.02), EXAS: 27.60 (+0.39), ARIA: 6.81 (+0.15), MNKD: 5.68 (+0.18)
3 Companies Growing Faster Than MannKind Corporation
Sean Williams, The Motley Fool - Motley Fool - Wed Dec 17, 6:03AM CST
Source: MannKind. MannKind shareholders have had quite the year. After more than doubling in the first half of the year, shares have since given back all of their gains and sit essentially unchanged. Despite the stalemate, MannKind could be on...
AKRX: 36.47 (+0.43), ALXN: 181.96 (+3.09), ACOR: 39.14 (+0.74), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)
4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Dec 16, 10:26AM CST
Despite the sell-off in late March, the biotech sector bounced back thanks to important product approvals, mergers and acquisitions, licensing agreements and strong performances.
MDVN: 99.23 (+1.23), OREX: 5.98 (+0.01), ENDP: 72.10 (+0.34), BMRN: 88.18 (+0.89), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), GERN: 3.06 (+0.05), AUXL: 34.40 (+0.18), AMGN: 160.67 (+3.15), MNKD: 5.68 (+0.18), CELG: 109.60 (+3.48)
3 Healthcare Stocks to Watch in 2015
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 15, 8:41AM CST
Source: Sanofi. The end of the year brings with it yuletide cheer, gatherings with friends and families, and perhaps even the swapping of holiday gifts. For healthcare investors, the end of the year also brings with it time to reflect on the year...
GILD: 91.29 (+1.84), ABBV: 66.21 (+1.86), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18), EXEL: 1.29 (-0.01)
Is MannKind Corporation in Bed With Crooks? And Should Investors Care?
Brian Orelli, The Motley Fool - Motley Fool - Fri Dec 12, 6:45AM CST
MannKind 's marketing partner Sanofi might be in big trouble. In a lawsuit filed last week, a former Sanofi employee claims she was fired after resisting the approval of nine contracts with consulting firms worth $34 million, because she...
SFY: 4.47 (-0.06), MNKD: 5.68 (+0.18)
Critical Alerts For MannKind, Merck, Alnylam Pharmaceuticals, Nu Skin Enterprises and Organovo Released By InvestorsObserver
PR Newswire - Tue Dec 09, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MNKD, MRK, ALNY, NUS and ONVO.
ALNY: 93.52 (+0.97), ONVO: 6.84 (+0.03), NUS: 45.27 (+0.78), MRK: 57.46 (+0.25), MNKD: 5.68 (+0.18)
Mannkind Reality Check Redux: 82.4 Million Reasons To Leave Your Lover!
Looking For Diogenes - at Seeking Alpha - Tue Dec 09, 1:36AM CST
MNKD: 5.68 (+0.18)
Biotech Weekly: Everything You Want To Know About Small Cap Biotech Cult Stocks
Daniel Ward - at Seeking Alpha - Mon Dec 08, 10:35AM CST
HEB: 0.22 (-0.02), IBIO: 0.68 (-0.04), MNKD: 5.68 (+0.18), ARNA: 3.57 (-0.01)
Brinson Patrick's Christopher S. James: All Catalysts Are Not Created Equal
Life Sciences Report - Seeking Alpha - Fri Dec 05, 7:55AM CST
Why do some good-news milestones cause stocks to languish, or even fall? Neurosurgeon Christopher James, managing director and senior biotechnology analyst at Brinson Patrick Securities, performs due diligence on stocks, in part, by connecting his...
BCRX: 11.83 (+0.76), STEM: 0.90 (+0.03), RTRX: 12.92 (+0.19), RGLS: 14.78 (+0.24), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)
Losing Confidence In MannKind
Orange Peel Investments - at Seeking Alpha - Fri Dec 05, 7:13AM CST
MNKD: 5.68 (+0.18)
MannKind: Strategy, Accounting, And Technosphere At Piper Jaffray Healthcare Conference
Psycho Analyst - at Seeking Alpha - Thu Dec 04, 7:36AM CST
MNKD: 5.68 (+0.18), SNY: 46.35 (+0.50)
MannKind: The Newest Bear Talking Point Is Absurd
The Kumquat - at Seeking Alpha - Fri Nov 28, 7:22AM CST
MNKD: 5.68 (+0.18), SNY: 46.35 (+0.50)
Will Insulin Pricing Be MannKind Corporation's Downfall?
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 26, 7:15AM CST
The biggest worry for MannKind has been whether doctors would prescribe its inhaled insulin drug, Afrezza, which would take market share away from injected insulin currently prescribed by physicians . But there might be a bigger concern: whether...
NVO: 43.80 (+1.08), LLY: 70.16 (+0.42), SNY: 46.35 (+0.50), MNKD: 5.68 (+0.18)
MannKind Corporation to Present at The 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 4:00PM CST
MannKind Corporation (Nasdaq:MNKD), focused on discovering, developing and commercializing therapeutic products for diabetes, announced today that it will present at The 26 Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3:00 PM (ET) at the New York Palace Hotel in New York City.
MNKD: 5.68 (+0.18)